Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Advances in Therapy|July 24, 2021
Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell LymphomaSophie Snyder, Karen C Chung, Monika P Jun, et al.Transplantation and Cellular Therapy|March 30, 2022
Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United StatesScott J Keating, Tao Gu, Monika P Jun, et al.Advances in Therapy|July 19, 2021
Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of CareSophie Snyder, Tina Albertson, Jacob Garcia, et al.Future Oncology (London, England)|June 24, 2024
Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspectiveMatthew Lei, Qianyi Li, Ken O'Day, et al.Pharmacoeconomics - Open|February 7, 2022
Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell LymphomaTimothy A Howell, Louis S Matza, Monika P Jun, et al.Journal of Medical Economics|September 10, 2024
Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: a retrospective claims analysis (2015-2020)Monika P Jun, Alex Mutebi, Anindit Chhibber, et al.Blood Advances|March 15, 2021
Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trialJeremy S Abramson, Tanya Siddiqi, Jacob Garcia, et al.Pageof 1